To Analyze the Association between the Polymorphism of NOS3 Gene VNTR in ADPKD

Authors

  • Shiva Nagendra Reddy Annapareddy Assistant Professor, Department of Nephrology, NRI Medical College & Hospital, Chinakakani, Guntur, Andhra Pradesh, India
  • Pratap Duggirala Assistant Professor, Department of Plastic Surgery, NRI Medical College & Hospital, Chinakakani, Guntur, Andhra Pradesh, India.

DOI:

https://doi.org/10.48165/1rw37z30

Keywords:

Polymerase chain reaction, Autosomal dominant polycystic kidney disease, VNTR, CKD

Abstract

Background: Autosomal dominant polycystic kidney disease (ADPKD) is an inherited disorder, and it is mainly associated with renal cyst  formation. Endothelial nitric oxide plays a crucial role in the control of local hemodynamics and systemic blood pressure. Thus, it has been  proposed that gene coding for endothelial nitric oxide synthase (eNOS) could have a modifying effect on hypertension and related  complications in autosomal dominant polycystic kidney disease (ADPKD). As endothelial dysfunction and oxidative stress are evident early in  ADPKD patients, eNOS holds therapeutic promise in the treatment of ADPKD. Objectives: The aim of the present investigation is to  determine the association between NOS3 27-bp VNTR in ADPKD patients and also investigate the role of progression of renal disease in  ADPKD. Subjects and Methods: In the present study, we investigated by studying the rural population of 50 ADPKD patients and 90  unrelated healthy controls admitted in Dept .of Nephrology, NRI Medical College & Hospital, Andhra Pradesh, India. Genetic analysis was  mainly performed by PCR and agarose gel electrophoresis. Genotype comparison was observed between control and ADPKD. Results:  Dyspnea was the most common symptom at presentation, being present in 35 (100 %) of the patients. Cough with or without expectoration was  All three genotypes of NOS3 were observed in both cases and controls of the present study. In both cases and controls wild type genotype is  more followed by heterozygote and minor genotypes. Blood Urea Nitrogen and creatinine is more in the controls when compared to the  ADPKD patients. The other core electrolytes are shown to be in the normal range in both case and controls of the present study. Glomerular  filtration rate is also exhibited differences between cases and controls. None of the biochemical variable has shown significant differences  among NOS3 genotypes. But the difference in glomerular filtration rate is significant among different genotypes. Conclusion: The present  study confirms the significant association between the 27-bp VNTR and CKD advancement among the ADPKD patients in the rural  population. 

References

1. Davies, F, Coles, GA, Harper, PS, et al. Polycystic kidney disease re evaluated: A population-based study. Q J Med 1991; 79:477. 2. Gabow, PA. Medical progress: Autosomal dominant polycystic kidney disease. N Engl J Med 1993; 329:332.

3. Levy, M, Feingold, J. Estimating prevalence in single-gene kidney diseases progressing to renal failure. Kidney Int 2000; 58:925. 4. Harris, PC, Torres, VE. Autosomal dominant polycystic kidney disease. Gene Clinics Online Reviews at Gene Tests-Gene Clinics

(University of Washington, Seattle, 2002).

5. Grantham, JJ. Clinical practice. Autosomal dominant polycystic kidney disease. N Engl J Med 2008; 359:1477.

6. Hateboer, N, v Dijk, MA, Bogdanova, N, et al. Comparison of phenotypes of polycystic kidney disease types 1 and 2. Lancet 1999; 353:103.

7. Parfrey, PS, Bear, JC, Morgan, J, et al. The diagnosis and prognosis of autosomal dominant polycystic kidney disease. N Engl J Med 1990; 323:1085.

8. Breuning, MH, Reeders, ST, Brunner, H, et al. Improved early diagnosis of adult polycystic kidney disease with flanking DNA markers. Lancet 1987; 2:1359.

9. Arnaout, MA. The vasculopathy of autosomal dominant polycystic kidney disease: insights from animal models. Kidney Int 2000; 58:2599.

10. Igarashi, P, Somlo, S. Genetics and pathogenesis of polycystic kidney disease. J Am Soc Nephrol 2002; 13:2384.

11. Peters, DJ, Spruit, L, Ravine, D, et al. Chromosome 4 localization of a second gene for autosomal dominant polycystic kidney disease. Nat Genet 1993; 5:359.

12. Pei, Y, He, H, Wang, K, et al. A spectrum of mutations in the polycystic kidney disease-2 (PKD2) gene from eight Canadian kindreds. J Am Soc Nephrol 1998; 9:1853.

13. Torra, R, Viribay, M, Telleria, D, et al. Seven novel mutations of the PKD2 gene in families with autosomal dominant polycystic kidney disease. Kidney Int 1999; 56:28.

14. Daoust, MC, Reynolds, DM, Bichet, DG, Somlo, S. Evidence for a third genetic locus for autosomal dominant polycystic kidney disease. Genomics 1995; 25:733.

15. de Almeida, E, Prata, MM, de Almeida, S, Lavinha, J. Long-term follow-up of a family with autosomal dominant polycystic kidney disease type 3. Nephrol Dial Transplant 1999; 14:631.

16. Reed, B, McFann, K, Kimberling, WJ, et al. Presence of de novo mutations in autosomal dominant polycystic kidney disease patients without family history. Am J Kidney Dis 2008; 52:1042.

17. The European Polycystic Kidney Disease Consortium. The PKD1 gene encodes a 14 kb transcript and lies within a duplicated region on chromosome 16. Cell 1994; 77:88.

18. Wang D, Iversen J, Strandgaard S. Endothelium-dependentrelaxation of small resistance vessels is impaired in patientswith autosomal dominant polycystic kidney disease. J Am SocNephrol 2000; 11: 1371–1376.

19. Moncada S, Higgs A. The L-arginine–nitric oxide pathway.N Engl J Med 1993; 329: 2002–2012.

20. Marsden PA, Heng HH, Scherer SW et al. Structure andchromosomal localization of the human constitutive endothelial nitric oxide synthase gene. J Biol Chem 1993; 268: 17478–17488.

21. Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R,Zeiher AM. Activation of nitric oxide synthase in endothelial cells by Akt dependent phosphorylation. Nature 1999; 399:601–605.

22. Noiri E, Satoh H, Taguchi J et al. Association of eNOSGlu298Asp polymorphism with end-stage renal disease.Hypertension 2002; 40: 535–540.

23. Arora, S. et al. International Journal of Collaborative Research on Internal Medicine & Public Health Vol. 1 No. 2 (April 2009) pp. 56- 71.

24. Yoon Y, Song J, Hong SH, et al. Plasma nitric oxide concentrations and nitric oxide synthase gene polymorphisms in coronary artery disease. Clin Chem 2000;46:1626–30.

25. Persu A, Stoenoiu MS, Messiaen T et al. Modifier effect ofENOS in autosomal dominant polycystic kidney disease.Hum Mol Genet 2002; 11: 229–241.

26. Zatz R, de Nucci G. Effects of acute nitric oxide inhibition on rat glomerular microcirculation. Am J Physiol. 1991 Aug;261(2 Pt 2):F360-3

27. Baylis C, Mitruka B, Deng A. Chronic blockade of nitric oxide synthesis in the rat produces systemic hypertension and glomerular damage. J Clin Invest. 1992 Jul;90(1):278-81.

28. Wang D, Iversen J, Strandgaard S. Endothelium-dependentrelaxation of small resistance vessels is impaired in patientswith autosomal dominant polycystic kidney disease. J Am SocNephrol 2000; 11: 1371–1376.

29. Nakayama M, Yasue H, Yoshimura M, et al. T-786–>C mutation in the 5′-flanking region of the endothelial nitric oxide synthase gene is associated with coronary spasm. Circulation 1999;99:2864-2870.

Downloads

Published

2020-01-30

How to Cite

To Analyze the Association between the Polymorphism of NOS3 Gene VNTR in ADPKD . (2020). Academia Journal of Medicine, 2(2), 103–108. https://doi.org/10.48165/1rw37z30